Premium
Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12
Author(s) -
Srour Samer A.,
Devesa Susan S.,
Morton Lindsay M.,
Check David P.,
Curtis Rochelle E.,
Linet Martha S.,
Dores Graça M.
Publication year - 2016
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14061
Subject(s) - medicine , polycythaemia , relative survival , population , incidence (geometry) , polycythemia vera , myelofibrosis , myeloproliferative neoplasm , pacific islanders , myelodysplastic syndromes , epidemiology , cancer registry , bone marrow , physics , environmental health , optics
Descriptive epidemiological information on myeloproliferative neoplasms ( MPN s) and myelodysplastic ( MDS )/ MPN s is largely derived from single institution and European population‐based studies. Data obtained following adoption of the World Health Organization classification of haematopoietic neoplasms and JAK2 V617F mutation testing are sparse. Using population‐based data, we comprehensively assessed subtype‐specific MPN and MDS / MPN incidence rates ( IR s), IR ratios ( IRR s) and relative survival ( RS ) in the United States (2001–12). IR s were highest for polycythaemia vera ( PV ) ( IR = 10·9) and essential thrombocythaemia ( ET ) ( IR = 9·6). Except for ET and mastocytosis, overall IR s were significantly higher among males ( IRR s = 1·4–2·3). All evaluable MPN s were associated with lower IR s among Hispanic whites than non‐Hispanic whites ( NHW s), with the exception of BCR‐ABL1 ‐positive chronic myeloid leukaemia ( CML ), chronic eosinophilic leukaemia ( CEL ) and juvenile myelomonocytic leukaemia. Except for CEL , Asians/Pacific Islanders had significantly lower MPN IR s than NHW s. ET , MPN ‐unclassifiable and CEL IR s were 18%, 19% and 60% higher, respectively, among blacks than NHW s. Five‐year RS was more favourable for younger (<60 years) than older individuals and for women compared with men, except for PV at older ages. RS was highest (>90%) for younger PV and ET patients and lowest (<20%) for older chronic myelomonocytic leukaemia and atypical BCR‐ABL1 ‐negative CML patients. Varying MPN and MDS / MPN incidence patterns by subtype support distinct aetiologies and/or susceptible populations. Decreased survival rates as compared to that expected in the general population were associated with every MPN subtype, highlighting the need for new treatments, particularly among older individuals.